Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11218371 | PMC |
| http://dx.doi.org/10.1186/s13019-024-02942-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Association of Cardiac CT-Derived Epicardial Adipose Tissue With Atrial Fibrillation in Patients Without Left Atrial Fibrosis as Defined by Endocardial Voltage Mapping.
J Cardiovasc Electrophysiol
January 2025
Division of Cardiology, Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada.
Article Synopsis
- Epicardial adipose tissue (EAT) is linked to atrial fibrillation (AF) and atrial fibrosis, but many AF patients show no signs of left atrial (LA) fibrosis. This study compared EAT levels in AF patients without LA fibrosis to matched controls without AF.
- AF patients without LA fibrosis had significantly higher total and regional volumes of EAT compared to controls, indicating that EAT may play a role in AF development even when LA fibrosis is absent.
- The study found no differences in EAT volumes between AF patients with and without LA fibrosis and no significant link between EAT volume and AF recurrence after catheter ablation.
Pericoronary adipose tissue radiomics features as imaging markers for coronary artery disease risk assessment: insights from gene expression analysis.
Cardiovasc Diabetol
December 2024
Imaging Center, The First Affiliated Hospital of Xinjiang Medical University, No 137, LiYuShan South Road, Urumqi, 830011, Xinjiang, China.
Aims: This study aimed to explore the correlation between radiomics features of pericoronary adipose tissue (PCAT) and gene expression in patients with coronary artery disease (CAD), with the goal of identifying novel imaging biomarkers for evaluating CAD.
Methods: Between November 2021 and May 2022, data were collected from 60 patients diagnosed with CAD who underwent coronary artery bypass grafting (CABG) and coronary computed tomography angiography (CCTA). Samples of PCAT, three additional adipose tissue types, and peripheral venous blood were analysed.
Cardiac resynchronization therapy by pacing the right ventricular dorsal site of inflow and anterior outflow for congenitally corrected transposition of the great arteries: a case report.
Eur Heart J Case Rep
December 2024
Department of Pediatrics, Niigata University, 757 Asahimachidori Ichibancho, Niigata City, Niigata 951-8510, Japan.
Background: Evidence regarding cardiac resynchronization therapy (CRT) for congenitally corrected transposition of the great arteries (ccTGA) is insufficient. The timing to perform CRT and optimal pacing sites have not been systematically studied. We performed CRT for ccTGA with a complete atrioventricular block (CAVB) by pacing the dorsal site of right ventricular inflow (dRVI) and anterior RV outflow tract (aRVOT).
View Article and Find Full Text PDFSGLT2 inhibitors reduce epicardial adipose tissue more than GLP-1 agonists or exercise interventions in patients with type 2 diabetes mellitus and/or obesity: A systematic review and network meta-analysis.
Diabetes Obes Metab
December 2024
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Background: Epicardial adipose tissue (EAT) plays a significant role in several cardiovascular diseases. As a correctable risk factor and potential therapeutic target, reducing EAT has multiple cardiovascular benefits, especially in those with abnormal glucolipid metabolism. The objective of this research was to compare the effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) agonists, and exercise on the thickness of EAT and indicators of glucolipid metabolism in people with type 2 diabetes mellitus (T2DM), obesity, and T2DM with obesity.
View Article and Find Full Text PDFTirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy.
J Am Coll Cardiol
November 2024
Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, Texas and Imperial College, London UK.
Article Synopsis
- Obesity is linked to heart failure with preserved ejection fraction (HFpEF), characterized by changes in heart structure and increased epicardial adipose tissue (EAT), which can lead to negative health outcomes.
- The SUMMIT trial's CMR substudy aimed to assess how tirzepatide influenced cardiac structure and function in patients with obesity-related HFpEF, focusing on its potential to lower left ventricular (LV) mass and EAT.
- Results showed that tirzepatide treatment significantly reduced LV mass by 11 g and paracardiac adipose tissue by 45 ml compared to placebo, with changes in LV mass correlated to body weight and other cardiac measures.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!